RUNX1 and acute myeloid leukemia: Clinically, BCOR-mutant AML has inferior outcomes (Figure S.1.A), especially when co-mutated with cohesin, RUNX1, or DNMT3A [6, 7], with increased chemoresistance at relapse [7].